References
- Saver JL. Clinical practice. Cryptogenic stroke. N Engl J Med 2016;374:2065-74
- Alsheikh-Ali AA, Thaler DE, Kent DM. Patent foramen ovale in cryptogenic stroke: incidental or pathogenic? Stroke 2009;40:2349-55
- Grau AJ, Weimar C, Buggle F, et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke 2001;32:2559-66
- Putaala J, Metso AJ, Metso TM, et al. Analysis of 1008 consecutive patients aged 15 to 49 with first-ever ischemic stroke: the Helsinki young stroke registry. Stroke 2009;40:1195-203
- Lerdal A, Bakken LN, Rasmussen EF, et al. Physical impairment, depressive symptoms and pre-stroke fatigue are related to fatigue in the acute phase after stroke. Disabil Rehabil 2011;33:334-42
- Glader E-L, Stegmayr B, Asplund K. Poststroke fatigue: a 2-year follow-up study of stroke patients in Sweden. Stroke 2002;33:1327-33
- Luengo-Fernandez R, Gray AM, Bull L, et al. Quality of life after TIA and stroke: ten-year results of the Oxford Vascular Study. Neurology 2013;81:1588-95
- Saka O, McGuire A, Wolfe C. Cost of stroke in the United Kingdom. Age Ageing 2009;38:27-32
- National Audit Office. Progress in improving stroke care - Report on the findings from our modelling of stroke care provision [Internet]. National Audit Office, United Kingdom; 2010. Available at: https://www.nao.org.uk/wp-content/uploads/2010/02/0910291_modelling.pdf
- Carroll JD, Saver JL, Thaler DE, et al. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med 2013;368:1092-100
- Kitsios GD, Dahabreh IJ, Abu Dabrh AM, et al. Patent foramen ovale closure and medical treatments for secondary stroke prevention: a systematic review of observational and randomized evidence. Stroke 2012;43:422-31
- Mas J-L, Derumeaux G, Guillon B, et al. Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med 2017;377:1011-21
- Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes of patent foramen ovale closure or medical therapy after stroke. N Engl J Med 2017;377:1022-32
- Søndergaard L, Kasner SE, Rhodes JF, et al. Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med 2017;377:1033-42
- Tirschwell DL, Turner M, Smalling RW, et al. Cost-effectiveness of percutaneous closure of a patent foramen ovale after a cryptogenic stroke in the context of the UK healthcare system. HTAi 2017 Annual Meeting. Rome, Italy; 2017
- Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Mak Int J Soc Med Decis Mak 1993;13:322-38
- Royal College of Physicians. National clinical guideline for stroke. Intercollegiate Stroke Working Party United Kingdom; 2016. Fifth Edition
- Von Klemperer K, Kempny A, Pavitt CW, et al. Device closure for patent foramen ovale following cryptogenic stroke: a survey of current practice in the UK. Open Heart 2017;4:e000636
- St. Jude Medical. RESPECT trial results submitted by St. Jude Medical to FDA as part of the Circulatory System Devices Panel for AMPLATZER PFO Occluder for the prevention of recurrent ischemic stroke [Internet]. St. Jude Medical, St. Paul, MN; 2016. p 123. Available at: https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/CirculatorySystemDevicesPanel/UCM502195.pdf
- Office for National Statistics. National life tables: United Kingdom [Internet] Office for National Statistics, United Kingdom; 2015. Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesunitedkingdomreferencetables
- Li L, Yiin GS, Geraghty OC, et al. Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study. Lancet Neurol 2015;14:903-13
- Office of National Statistics. CPI INDEX: Medical services (S) 2015 = 100 [Internet]. Office of National Statistics, United Kingdom; 2017. Available at: https://www.ons.gov.uk/economy/inflationandpriceindices/timeseries/dkc3/mm23
- eurostat European Commission. Eurostat-OECD methodological manual on purchasing power parities [Internet]. Eurostat European Commission, European Union; 2012. Available at: https://www.oecd.org/std/prices-ppp/PPP%20manual%20revised%202012.pdf
- Luengo-Fernandez R, Gray AM, Rothwell PM, et al. A population-based study of hospital care costs during 5 years after transient ischemic attack and stroke. Stroke J Cereb Circ 2012;43:3343-51
- Johnson BH, Bonafede MM, Watson C. Short- and longer-term health-care resource utilization and costs associated with acute ischemic stroke. Clin Outcomes Res CEOR 2016;8:53-61
- Joint Formulary Committee, editor. BNF 72 (British National Formulary September 2016–March 2017). 72nd Revised edition. Pharmaceutical Press, United Kingdom; 2016
- NHS Electronic Drug Tariff_aspirin. UK drug tariff for aspirin 75mg [Internet], United Kingdom; 2017. Available at: http://www.drugtariff.nhsbsa.nhs.uk/#/00469069-DB/DB00469065/Home
- NHS Electronic Drug Tariff_clopidogrel. UK drug tariff for clopidogrel 75mg [Internet], United Kingdom; 2017. Available at: http://www.drugtariff.nhsbsa.nhs.uk/#/00469069-DB/DB00469065/Home
- Evola S, Kauroo BAW, Trovato RL, et al. The percutaneous closure of patent foramen ovale (PFO): impact on the quality of life. Int J Cardiol 2013;168:1622-3
- Mirzada N, Ladenvall P, Hansson P-O, et al. Quality of life after percutaneous closure of patent foramen ovale in patients after cryptogenic stroke compared to a normative sample. Int J Cardiol 2018;257:46-9
- Guide to the methods of technology appraisal 2013 (PMG9) [Internet]. National Institute of Health and Care Excellence, United Kingdom; 2013. Available at: https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781
- Nendaz MR, Sarasin FP, Junod AF, et al. Preventing stroke recurrence in patients with patent foramen ovale: antithrombotic therapy, foramen closure, or therapeutic abstention? A decision analytic perspective. Am Heart J 1998;135:532-41
- Pickett CA, Villines TC, Ferguson MA, et al. Cost effectiveness of percutaneous closure versus medical therapy for cryptogenic stroke in patients with a patent foramen ovale. Am J Cardiol 2014;114:1584-9
- NHS Commissioning. Commissioning through evaluation [Internet], United Kingdom, 2017. Available at: https://www.england.nhs.uk/commissioning/spec-services/npc-crg/comm-eval/
- Tirschwell DL, Marks DS, MacDonald LA, et al. Cost-effectiveness of percutaneous PFO closure in patients with history of cryptogenic stroke in the United States. ISPOR 22nd Annual International Meeting. Boston, MA; 2017
- Cohen M, Daniela M, Lorber A. Patent foramen ovale closure in post-CVA/TIA patients: psychological distress, quality of life and optimism. Int J Clin Pract 2010;64:182-7
- Lin K, Fu T, Wu C, et al. Assessing the stroke-specific quality of life for outcome measurement in stroke rehabilitation: minimal detectable change and clinically important difference. Health Qual Life Outcomes 2011;9:5